The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis

SpringerPlus

Table 3 Results of an MTC of percentage change in inflammatory lesion count between ivermectin 1 % cream QD and comparators at 12 weeks

Comparator treatment	12 weeks (Absolute difference, 95 % Crl) 14 studies
Azelaic acid 15 % gel QD	−15.87 (−29.02 to −2.87)
Azelaic acid 15 % gel BID	−8.04 (−12.69 to −3.43)
Metronidazole 0.75 % cream BID	−9.92 (−13.58 to −6.35)
Metronidazole 1 % gel BID	18.11 (−3.63 to 39.95)
Metronidazole 1 % gel BID + doxycycline 40 mg QD	−0.04 (−25.21 to 25.65)
Sodium sulfacetamide 10 % + sulfur 5 % cream BID	−1.68 (−10.21 to 6.85)
Vehicle	−21.42 (−25.20 to −17.60)

Negative values indicate a greater percentage reduction in the inflammatory lesion count with ivermectin 1 % cream QD than with the comparator. A negative Crl that does not cross 0 indicates a significantly higher likelihood of patients using ivermectin 1 % cream QD experiencing a greater reduction in inflammatory lesion count (significant differences between treatments indicated in italic). Studies contributing to 12 week analysis: Stein et al. (2014), Gold et al. (2014a), Galderma (2006, 2014), Torok et al. (2005), Elewski et al. (2003), Thiboutot et al. (2003, 2008), NCT00617903 (2013), Draelos et al. (2013, 2015), Tan et al. (2002), Fowler (2007a); 3 week and 9 week results available in Additional file 1: Table 8. MTC results are derived from a fixed effects model
BID twice daily, Crl credible interval, MTC mixed treatment comparison, QD once daily